Nxera Pharma Co., Ltd. (TYO:4565)
Japan · Delayed Price · Currency is JPY 1,195.00
-38.00 (-3.08%)
Sep 16, 2026, 3:30 PM JST
Nxera Pharma Ratios and Metrics
Market cap in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 112,666 | 74,839 | 94,216 | 127,103 | 175,151 | 155,210 | |
Market Cap Growth | 26.27% | -20.57% | -25.87% | -27.43% | 12.85% | 7.00% |
Enterprise Value | 149,324 | 109,518 | 114,757 | 158,025 | 143,645 | 134,496 |
Last Close Price | 1233.00 | 827.00 | 1048.00 | 1421.00 | 2138.00 | 1904.00 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 458.51 | 152.62 |
Forward PE | 24.25 | 14.88 | 48.75 | 62.51 | 62.98 | 37.67 |
PS Ratio | 3.37 | 2.53 | 3.27 | 9.96 | 11.25 | 8.76 |
PB Ratio | 1.74 | 1.23 | 1.38 | 1.90 | 3.02 | 2.70 |
P/TBV Ratio | - | - | - | - | 5.14 | 4.67 |
P/FCF Ratio | 418.83 | - | - | - | 18.10 | 22.49 |
P/OCF Ratio | 128.91 | - | - | - | 17.60 | 21.88 |
PEG Ratio | - | 0.31 | 0.31 | 0.71 | 1.03 | 1.77 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.47 | 3.70 | 3.98 | 12.38 | 9.23 | 7.59 |
EV/EBITDA Ratio | 165.55 | - | - | - | 34.56 | 16.43 |
EV/EBIT Ratio | - | - | - | - | 51.08 | 19.46 |
EV/FCF Ratio | 555.11 | - | - | - | 14.85 | 19.49 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.84 | 0.94 | 0.99 | 1.11 | 0.51 | 0.51 |
Debt / EBITDA Ratio | 72.16 | - | - | - | 7.15 | 3.57 |
Debt / FCF Ratio | 202.25 | - | - | - | 3.07 | 4.24 |
Net Debt / Equity Ratio | 0.57 | 0.61 | 0.46 | 0.37 | -0.64 | -0.54 |
Net Debt / EBITDA Ratio | 48.62 | -9.48 | -12.01 | -3.14 | -8.86 | -3.76 |
Net Debt / FCF Ratio | 136.28 | -11.88 | -3.84 | -4.10 | -3.81 | -4.46 |
Asset Turnover | 0.24 | 0.21 | 0.19 | 0.10 | 0.16 | 0.20 |
Inventory Turnover | 0.85 | 0.81 | 1.30 | - | - | - |
Quick Ratio | 1.88 | 1.83 | 3.04 | 3.55 | 16.90 | 8.67 |
Current Ratio | 2.66 | 2.54 | 3.70 | 3.79 | 17.09 | 8.73 |
Return on Equity (ROE) | -11.94% | -19.35% | -7.15% | -11.53% | 0.66% | 1.85% |
Return on Assets (ROA) | -1.64% | -3.61% | -2.68% | -5.07% | 1.79% | 4.98% |
Return on Invested Capital (ROIC) | -3.47% | -8.34% | -6.90% | -18.43% | 4.17% | 24.83% |
Return on Capital Employed (ROCE) | -3.10% | -7.10% | -4.90% | -7.40% | 2.90% | 7.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -6.92% | -16.74% | -5.13% | -5.66% | 0.22% | 0.66% |
FCF Yield | 0.24% | -4.16% | -8.75% | -4.78% | 5.52% | 4.45% |
Buyback Yield / Dilution | -0.69% | -0.61% | -8.74% | 0.09% | -0.71% | -3.16% |